RxDoctor Payments Data

Michelle Chaney

Optometrist · Laramie, WYNPI 1528030988

Payments from drug & device makers

What this record shows

16 manufacturers reported payments, led by Alcon at 56.9% of the total. Reporting peaked in 2024 at $2,515 and has fallen 83.9% since, to $406 in 2025. Among optometrist clinicians in WY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,698in general payments, 2019–2025

Across 51 payments — averaging $72.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$311
  • Harrow Eye, LLC$267
  • Coopervision Inc.$162
  • Bausch & Lomb Americas Inc.$151
  • Johnson & Johnson Vision Care, Inc.$147
  • plus $556 from 10 others

What the payments were for

  • Speaking & faculty fees$2,00054%
  • Food & beverage$1,69846%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,698 in reported general payments places this provider in the 95th percentile of 102 optometrist providers in Wyoming.

See all optometrist providers in Wyoming

Medicare billing

Part B allowed, 2024
$90,039
Medicare patients
556
Services billed
859

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine36$46,671
Cyclosporine39$31,675
LumiganBimatoprost25$14,017
Alphagan PBrimonidine Tartrate20$4,364
Travoprost20$3,369
Latanoprost138$1,389
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol13$780
Prednisolone Acetate23$711
Fluorometholone12$583
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat27$502
Dorzolamide Hcl24$453
Brimonidine Tartrate19$332
Timolol Maleate58$305
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha21$255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Alphagan P$311$65,05381 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 102 optometrist providers in Wyoming.

Other optometrist in Laramie

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →